Short facts  
API Nalmefene
Technology Nasal
Indication Rescue medication opioid overdose
Development phase Phase 1
Expected filing with FDA -
In-house or partnership In-house

Unmet medical need

In 2017 more than 70,200 Americans died of an overdose. An increasing proportion died as a result of the use of synthetic opioid fentanyl and fentanyl analogs, which in 2017 were behind 30,000 of the deaths.1 Currently available naloxone-based rescue medications struggle to reverse effects of such opioids.

The concept

OX125 is based on a novel and unique technology developed to provide a rapidly acting nalmefene rescue medication with the aim to provide differentiated profile compared to currently marketed products and other products under development. Like naloxone, nalmefene is a full opioid receptor antagonist which reverses the effects of opioid agonists, while having a significantly longer half-life than naloxone.

1 National Institute on Drug Abuse